273 related articles for article (PubMed ID: 30125515)
21. Multimodality Imaging of Prostate Cancer.
Ghafoor S; Burger IA; Vargas AH
J Nucl Med; 2019 Oct; 60(10):1350-1358. PubMed ID: 31481573
[TBL] [Abstract][Full Text] [Related]
22. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
23. Recent developments in urologic oncology: positron emission tomography molecular imaging.
Bouchelouche K; Oehr P
Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
[TBL] [Abstract][Full Text] [Related]
24. New Targets for PET Molecular Imaging of Prostate Cancer.
Mena E; Lindenberg LM; Choyke PL
Semin Nucl Med; 2019 Jul; 49(4):326-336. PubMed ID: 31227055
[TBL] [Abstract][Full Text] [Related]
25. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
26. Prostate Cancer Local Recurrence Detected With Both
Gorin MA; Pienta KJ; Pomper MG; Rowe SP
Urology; 2017 Sep; 107():e9-e10. PubMed ID: 28641974
[TBL] [Abstract][Full Text] [Related]
27. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.
Siva S; Udovicich C; Tran B; Zargar H; Murphy DG; Hofman MS
Nat Rev Urol; 2020 Feb; 17(2):107-118. PubMed ID: 31937920
[TBL] [Abstract][Full Text] [Related]
28. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.
Nanni C; Schiavina R; Brunocilla E; Boschi S; Borghesi M; Zanoni L; Pettinato C; Martorana G; Fanti S
Clin Nucl Med; 2015 Aug; 40(8):e386-91. PubMed ID: 26053708
[TBL] [Abstract][Full Text] [Related]
29. PET imaging in urology: a rapidly growing successful collaboration.
Farolfi A; Koschel S; Murphy DG; Fanti S
Curr Opin Urol; 2020 Sep; 30(5):623-627. PubMed ID: 32701721
[TBL] [Abstract][Full Text] [Related]
30. The future of choline PET in the era of prostate specific membrane antigen.
Evangelista L; Cuppari L; Zattoni F; Mansi L; Bombardieri E
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):19-28. PubMed ID: 29383928
[TBL] [Abstract][Full Text] [Related]
31. Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT.
Cornelis FH; Durack JC; Morris MJ; Scher HI; Solomon SB
Clin Nucl Med; 2017 Dec; 42(12):e516-e518. PubMed ID: 29099733
[TBL] [Abstract][Full Text] [Related]
32. Current use of PSMA-PET in prostate cancer management.
Maurer T; Eiber M; Schwaiger M; Gschwend JE
Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
[TBL] [Abstract][Full Text] [Related]
33. Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker.
Huang SS; Wang X; Zhang Y; Doke A; DiFilippo FP; Heston WD
Prostate; 2014 May; 74(7):702-13. PubMed ID: 24615708
[TBL] [Abstract][Full Text] [Related]
34. Comparative immuno-Cerenkov luminescence and -PET imaging enables detection of PSMA
Maier FC; Wild AM; Kirchen N; Holm F; Fuchs K; Schwenck J; Maurer A; Wiehr S
Appl Radiat Isot; 2019 Jan; 143():149-155. PubMed ID: 30445280
[TBL] [Abstract][Full Text] [Related]
35. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and evaluation of novel prostate-specific membrane antigen-targeted aryl [
Wang Z; Zhu B; Jiang F; Chen X; Wang G; Ding N; Song S; Xu X; Zhang W
Bioorg Med Chem; 2024 May; 106():117753. PubMed ID: 38749342
[TBL] [Abstract][Full Text] [Related]
37. ¹⁸F-NaF PET/CT and ¹¹C-Choline PET/CT for the initial detection of metastatic disease in prostate cancer: overview and potential utilization.
Koo PJ; David Crawford E
Oncology (Williston Park); 2014 Dec; 28(12):1057-62, 1064-5. PubMed ID: 25738199
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.
Chau A; Gardiner P; Colletti PM; Jadvar H
Clin Nucl Med; 2018 Jul; 43(7):e226-e231. PubMed ID: 29762238
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
